A Trans-Tasman collaboration involving New Zealand’s Te Herenga Waka — Victoria University of Wellington’s Ferrier Research Institute and the Malaghan Institute of Medical Research, along with Australia’s Peter Doherty Institute for Infection and Immunity, has developed an innovative mRNA-based vaccine against the malaria-causing parasite, Plasmodium. This breakthrough was made possible through years of cumulative research led by Professor Gavin Painter, among others.
The distinctive approach of this vaccine generates resident memory cells in the liver, crucial in combating malaria. It underscores the vast potential of RNA technology in addressing global health crises and highlights the escalating proficiency in mRNA vaccine development in Australasia.
The team originally explored peptide-based vaccines but shifted to RNA-based vaccines in 2018. This strategic redirection proved fruitful due to the recent success of RNA technology in vaccine development. Unlike peptide-based vaccines which only contain small protein fragments, the mRNA vaccines encode an entire malaria protein, allowing for a broader, more protective immune response.
Further enhancing the vaccine’s potency, it has been combined with an adjuvant developed for cancer immunotherapies. This additive targets liver-specific immune cells, localizing the RNA vaccine response to the liver, where the malaria parasite matures. This approach leverages tissue-resident memory T-cells, distinct from the neutralizing antibodies mechanism used in the COVID-19 vaccine, halting the parasite’s development in the liver to prevent infection spread.
A significant advantage of this vaccine, as highlighted by Dr. Lauren Holz, is its efficacy irrespective of previous malaria exposure. Unlike other vaccines that falter in malaria-endemic regions, this novel vaccine remains effective, generating protective liver-specific immune cells. The team’s future objective is to advance this promising vaccine into human clinical trials, a process projected to span several years.
![GMP mRNA](https://static.packgene.com/wp-content/uploads/2023/05/GMP-mRNA.jpg)
Check out our mRNA service to expedite your vaccine research
Journal Reference:
Mitch Ganley, Lauren E. Holz, Jordan J. Minnell, Maria N. de Menezes, Olivia K. Burn, Kean Chan Yew Poa, Sarah L. Draper, Kieran English, Susanna T. S. Chan, Regan J. Anderson, Benjamin J. Compton, Andrew J. Marshall, Anton Cozijnsen, Yu Cheng Chua, Zhengyu Ge, Kathryn J. Farrand, John C. Mamum, Calvin Xu, Ian A. Cockburn, Katsuyuki Yui, Patrick Bertolino, Stephanie Gras, Jérôme Le Nours, Jamie Rossjohn, Daniel Fernandez-Ruiz, Geoffrey I. McFadden, David F. Ackerley, Gavin F. Painter, Ian F. Hermans, William R. Heath. mRNA vaccine against malaria tailored for liver-resident memory T cells. Nature Immunology, 2023; DOI: 10.1038/s41590-023-01562-6
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha™ 293 cell AAV high-yield platform and the π-Omega™ plasmid high-yield platform. PackGene’s mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
![](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)
Plasmids GMP Services
Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE
![](https://static.packgene.com/wp-content/uploads/2023/01/10-2.png)
AAV GMP Services
Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
![aav icon](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)
Technology Platforms
PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE